Veru (STU:FMW) Gross-Profit-to-Asset % : 3.57% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Veru Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Veru's annualized Gross Profit for the quarter that ended in Mar. 2024 was €2.50 Mil. Veru's average Total Assets over the quarter that ended in Mar. 2024 was €69.97 Mil. Therefore, Veru's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 3.57%.

Veru Gross-Profit-to-Asset % Historical Data

The historical data trend for Veru's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Gross-Profit-to-Asset % Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

43.59

56.54

41.74

21.45

7.72

Veru Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															18.69	6.73	9.93	6.99	3.57

Competitive Comparison of Veru's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Veru's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veru's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Veru's Gross-Profit-to-Asset % falls into.

Veru Gross-Profit-to-Asset % Calculation

Veru's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Sep. 2023 )	/	( (Total Assets (A: Sep. 2022 )	+	Total Assets (A: Sep. 2023 ))	/ count )
	=	7.089	/	( (136.712	+	46.872)	/ 2 )
	=	7.089	/	91.792
	=	7.72 %

Veru's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	2.496	/	( (73.88	+	66.056)	/ 2 )
	=	2.496	/	69.968
	=	3.57 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Veru Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Veru's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (STU:FMW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

VERU:USA FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines